Keywords: japan, mhlw, grants, revlimid, orphan, status, different
Japan's MHLW grants Revlimid orphan status for two different indications
Article | 25 February 2008
Celgene International Sarl, the Switzerland-based unit of the US drugmaker, says that Revlimid (lenalidomide; CC-5013) has been granted Orphan Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
